Literature DB >> 30463677

ApoB in clinical care: Pro and Con.

Allan D Sniderman1, Jennifer G Robinson2.   

Abstract

Whether apoB adds significantly to the assessment of the risk and therapy of the atherogenic dyslipoproteinemias has been vigorously contested over many years. That trapping of apoB lipoprotein particles within the arterial wall is fundamental to the initiation and maturation of atherosclerotic lesions within the arterial wall is now widely accepted. At the same time, the concept that primary prevention should be based on the risk of a cardiovascular event, a measure that integrates the effects of age, sex, blood pressure, lipids and other factors, has also become widely accepted. Within the risk framework, the issue becomes whether apoB adds significantly to the assessment of risk. On the other hand, it can be argued that the risk model undervalues how important a role that LDL and blood pressure play as causes of atherosclerosis and that when considered as causes, the importance of apoB emerges. These are the two sides of the debate that will be presented in the article that follows: one will highlight the pros of measuring apoB, the second the cons. The reader can make up his or her mind which side of the issue they favour.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Causes; LDL C; Prevention; Risk; apoB; nonHDL C

Mesh:

Substances:

Year:  2018        PMID: 30463677     DOI: 10.1016/j.atherosclerosis.2018.11.001

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  A Modern Approach to Dyslipidemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

2.  A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test.

Authors:  Maureen Sampson; Anna Wolska; Russell Warnick; Diego Lucero; Alan T Remaley
Journal:  Clin Chem       Date:  2021-07-06       Impact factor: 8.327

3.  Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.

Authors:  Yunpeng Guan; Xiaoyu Hou; Peipei Tian; Luping Ren; Yong Tang; An Song; Jiajun Zhao; Ling Gao; Guangyao Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

4.  The Relationship between Blood Lipids and Risk of Atrial Fibrillation: Univariable and Multivariable Mendelian Randomization Analysis.

Authors:  Shengyi Yang; Rupak Pudasaini; Hong Zhi; Lina Wang
Journal:  Nutrients       Date:  2021-12-31       Impact factor: 5.717

5.  A new phenotypic classification system for dyslipidemias based on the standard lipid panel.

Authors:  Maureen Sampson; Rami A Ballout; Daniel Soffer; Anna Wolska; Sierra Wilson; Jeff Meeusen; Leslie J Donato; Erica Fatica; James D Otvos; Eliot A Brinton; Robert S Rosenson; Peter Wilson; Marcelo Amar; Robert Shamburek; Sotirios K Karathanasis; Alan T Remaley
Journal:  Lipids Health Dis       Date:  2021-11-27       Impact factor: 3.876

6.  Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease.

Authors:  Efstratios Karagiannidis; Dimitrios V Moysidis; Andreas S Papazoglou; Eleftherios Panteris; Olga Deda; Nikolaos Stalikas; Georgios Sofidis; Anastasios Kartas; Alexandra Bekiaridou; George Giannakoulas; Helen Gika; George Theodoridis; Georgios Sianos
Journal:  Cardiovasc Diabetol       Date:  2022-05-07       Impact factor: 9.951

Review 7.  Mass Spectrometry for the Monitoring of Lipoprotein Oxidations by Myeloperoxidase in Cardiovascular Diseases.

Authors:  Catherine Coremans; Cédric Delporte; Frédéric Cotton; Phillipe Van De Borne; Karim Zouaoui Boudjeltia; Pierre Van Antwerpen
Journal:  Molecules       Date:  2021-08-30       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.